(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
5 Fundamental Ways to employ a Criminal Legal counselor - 2Viable Correspondence: Building Solid Connections
- 3The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 4Finding the Force of Mentorship: Self-awareness Through Direction
- 5Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Travels to Dream Objections in Europe
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- German gas price bill signed into law, but consumers not impressed
- Find the Abilities Required for Advanced Advertising Position
- Is 'Stranger Things' releasing one last episode? The 'Conformity Gate' fan theory explained as speculation mounts.
- Iranian-linked drone attack kills Kurdish couple in northern Iraq
- Which European palace do you fantasy about visiting? Vote!
- Best Food Truck Cooking: Decision in favor of Your Number one!
